Literature DB >> 6573319

Cefotetan elimination in patients with varying degrees of renal dysfunction.

N Wright, R Wise, T Hegarty.   

Abstract

The pharmacokinetics of cefotetan following a 0.5 g intravenous dose were studied in 15 patients with varying degrees of renal failure. In patients with glomerular filtration rates (GFR) greater than 50 ml/min the serum half-life was between 3 and 5 h. The half-life increased to 15 h as the GFR fell to 10 ml/min. When the GFR was less than 10 ml/min the serum clearance of cefotetan was very variable, the half-life being between 15 and 50 h. Cefotetan was eliminated almost entirely by the kidneys. It is suggested that cefotetan 0.5 g 12-hourly is appropriate for patients with GFRs greater than 20 ml/min. For patients with GFRs between 10 and 20 ml/min 0.5 g every 24 h should avoid gross accumulation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6573319     DOI: 10.1093/jac/11.suppl_a.213

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Anti-anaerobic antimicrobial agents: cefoxitin, cefotetan, clindamycin, and metronidazole.

Authors:  J A Bosso; R A Prince
Journal:  Tex Heart Inst J       Date:  1990

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 3.  Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Ward; D M Richards
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

4.  Cefotetan pharmacokinetics in volunteers with various degrees of renal function.

Authors:  B R Smith; J L LeFrock; P T Thyrum; B A Doret; C Yeh; G Onesti; A Schwartz; J J Zimmerman
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of cefotetan.

Authors:  C Martin; L Thomachot; J Albanese
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.